Exploring the tumour environment: Cancer-associated fibroblasts as targets in cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 6, 2005, Pages 1217-1233

  Micke, Patrick ^a   Östman, Arne ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer associated fibroblast (CAF); Hepatocyte growth factor (HGF); Laser microdissection; Microarray; Myofibroblast; Platelet derived growth factor (PDGF); Stroma; Targeted therapy; Transforming growth factor (TGF 1)

Indexed keywords

ANTINEOPLASTIC AGENT; AP 12009; IMATINIB; LERDILIMUMAB; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METELIMUMAB; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; SCATTER FACTOR; SD 208; SIBROTUZUMAB; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

BASAL CELL CARCINOMA; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CELL FUNCTION; CELL HETEROGENEITY; CELL INTERACTION; CELL STRUCTURE; CELL TYPE; CLINICAL TRIAL; COLON CANCER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TARGETING; FIBROBLAST; GENE EXPRESSION PROFILING; GENETIC REGULATION; GLIOMA; HUMAN; INFLAMMATION; LUNG CANCER; MEDIATOR; MEDICAL DECISION MAKING; METASTASIS; MICROENVIRONMENT; MOLECULAR BIOLOGY; MYOFIBROBLAST; NONHUMAN; PANCREAS CANCER; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TREATMENT PLANNING; TUMOR CELL CULTURE; TUMOR PROMOTION; WOUND HEALING;

ANIMALS; CELL PROLIFERATION; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; HUMANS; NEOPLASMS;

EID: 28844444157     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.6.1217     Document Type: Review

References (147)

1. VOGELSTEIN B, KINZLER KW: Cancer genes and the pathways they control. Nat. Med. (2004) 10(8):789-799.
2. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100(1):57-70.
3. CAPDEVILLE R, BUCHDUNGER E, ZIMMERMANN J, MATTER A: Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug. Discov. (2002) 1(7):493-502.
4. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
5. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
6. JOENSUU H, ROBERTS PJ, SARLOMO-RIKALA M et al.: Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. (2001) 344(14):1052-1056.
7. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344(14):1038-1042.
8. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344(14):1031-1037.
9. BHOWMICK NA, NEILSON EG, MOSES HL: Stromal fibroblasts in cancer initiation and progression. Nature (2004) 432(7015):332-337.
10. BISSELL MJ, RADISKY D: Putting tumours in context. Nat. Rev. Cancer (2001) 1(1):46-54.
11. MICKE P, OSTMAN A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer (2004) 45(Suppl. 2):S163-S175.
12. MUELLER MM, FUSENIG NE: Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer (2004) 4(11):839-849.
13. ERICKSON AC, BARCELLOS-HOFF MH: The not-so innocent bystander: the microenvironment as a therapeutic target in cancer. Expert Opin. Ther. Targets (2003) 7(1):71-88.
14. FOLKMAN J, KALLURI R: Cancer without disease. Nature (2004) 427(6977):787.
15. FOLKMAN J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285(21):1182-1186.
16. OLSZEWSKI AJ, GROSSBARD ML, KOZUCH PS: The horizon of antiangiogenic therapy for colorectal cancer. Oncology (Huntingt) (2005) 19(3):297-306; discussion 306, 308, 317-233.
17. ROSENBERG SA, YANG JC, RESTIFO NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10(9):909-915.
18. VAN BAREN N, BONNET MC, DRENO B et al.: Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. (2005).
19. RONNOV-JESSEN L, PETERSEN OW. BISSELL MJ: Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Pbysiol. Rev. (1996) 76(1):69-125.
20. WILLIS R. Pathology of tumors. (ed.) Butterworth, London, (1960):130-140.
21. RONNOV-JESSEN L, PETERSEN OW, KOTELIANSKY VE, BISSELL MJ: The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J. Clin. Invest. (1995) 95(2):859-873.
22. DVORAK HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. (1986) 315(26):1650-1659.
23. BALKWILL F, MANTOVANI A: Inflammation and cancer: back to Virchow? Lancet (2001) 357(9255):539-545.
24. DOLBERG DS, HOLLINGSWORTH R, HERTLE M, BISSELL MJ: Wounding and its role in RSV-mediated tumor formation. Science (1985) 230(4726):676-678.
25. DUNHAM LJ: Cancer in man at site of prior benign lesion of skin or mucous membrane: a review. Cancer Res. (1972) 32(7):1359-1374.
26. KORNFELD D, EKBOM A, IHRE T: Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut (1997) 41(4):522-525.
27. PEEK RM, JR., BLASER MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer (2002) 2(1):28-37.
28. BRIGATI C, NOONAN DM, ALBINI A, BENELLI R: Tumors and inflammatory infiltrates: friends or foes? Clin. Exp. Metastasis (2002) 19(3):247-258.
29. BARCELLOS-HOFF MH: Integrative radiation carcinogenesis: interactions between cell and tissue responses to DNA damage. Semin. Cancer Biol. (2005) 15(2):138-148.
30. BARCELLOS-HOFF MH, BROOKS AL: Extracellular signaling through the microenvironment: a hypothesis relating carcinogenesis, bystander effects, and genomic instability. Radiat. Res. (2001) 156(5 Pt 2):618-627.
31. BARCELLOS-HOFF MH, RAVANI SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. (2000) 60(5):1254-1260.
32. OHUCHIDA K, MIZUMOTO K, MURAKAMI M et al.: Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. (2004) 64(9):3215-3222.
33. MOINFAR F, MAN YG, ARNOULD L et al.: Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res. (2000) 60(9):2562-2566.
34. KUROSE K, GILLEY K, MATSUMOTO S et al.: Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet. (2002) 32(3):355-357.
35. HU M, YAO J, CAI L et al.: Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. (2005) 37(8):899-905.
36. JACOBY RF, SCHLACK S, COLE CE et al.: A juvenile polyposis tumor suppressor locus at 10q22 is deleted from nonepithelial cells in the lamina propria. Gastroenterology (1997) 112(4):1398-1403.
37. KIARIS H, CHATZISTAMOU I, TRIMIS G et al: Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res. (2005) 65(5):1627-1630.
38. RONNOV-JESSEN L, PETERSEN OW: Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Invest. (1993) 68(6):696-707.
39. MOSES HL, YANG EY, PIETENPOL JA: TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell (1990) 63(2):245-247.
40. BISSELL DM: Chronic liver injury, TGF-beta, and cancer. Exp. Mol. Med. (2001) 33(4):179-190.
41. BONNER JC: Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. (2004) 15(4):255-273.
42. HAUPTMANN S, SIEGERT A, BERGER S et al.: Regulation of cell growth and the expression of extracellular matrix proteins in colorectal adenocarcinoma: a fibroblast-tumor cell coculture model to study tumor-host interactions in vitro. Eur. J. Cell Biol. (2003) 82(1):1-8.
43. DECOSSE JJ, GOSSENS C, KUZMA JF, UNSWORTH BR: Embryonic inductive tissues that cause histologic differentiation of murine mammary carcinoma in vitro. J. Natl Cancer Inst. (1975) 54(4):913-922.
44. DECOSSE JJ, GOSSENS CL, KUZMA JF, UNSWORTH BR: Breast cancer: induction of differentiation by embryonic tissue. Science (1973) 181(104):1057-1058.
45. COOPER M, PINKUS H: Intrauterine transplantation of rat basal cell carcinoma as a model for reconversion of malignant to benign growth. Cancer Res. (1977) 37(8 Pt 1):2544-2552.
46. MAEHARA N, MATSUMOTO K, KUBA K et al.: NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br. J. Cancer (2001) 84(6):864-873.
47. OLUMI AF, GROSSFELD GD, HAYWARD SW et al.: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. (1999) 59(19):5002-5011.
48. HAYWARD SW, WANG Y, CAO M et al.: Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. (2001) 61(22):8135-8142.
49. SATO N, MAEHARA N, GOGGINS M: Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res. (2004) 64(19):6950-6956.
50. ATULA S, GRENMAN R, SYRJANEN S: Fibroblasts can modulate the phenotype of malignant epithelial cells in vitro. Exp. Cell Res. (1997) 235(1):180-187.
51. KUNZ-SCHUGHART LA, HEYDER P, SCHROEDER J, KNUECHEL R. A heterologous 3-D coculture model of breast tumor cells and fibroblasts to study tumor-associated fibroblast differentiation. Exp. Cell Res. (2001) 266(1):74-86.
52. CAMPS JL, CHANG SM, HSU TC et al: Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc. Natl. Acad. Sci. USA (1990) 87(1):75-79.
53. NOEL A, NUSGENS B, LAPIERE CH, FOIDART JM: Interactions between tumoral MCF7 cells and fibroblasts on matrigel and purified laminin. Matrix (1993) 13(4):267-273.
54. GLEAVE M, HSIEH JT, GAO CA, VON ESCHENBACH AC, CHUNG LW: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. (1991) 51(14):3753-3761.
55. TUXHORN JA, MCALHANY SJ, DANG TD, AYALA GE, ROWLEY DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model, Cancer Res. (2002) 62(11):3298-3307.
56. PARROTT JA, NILSSON E, MOSHER R et al.: Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. Mol. Cell. Endocrinol. (2001) 175(1-2):29-39.
57. BARCLAY WW, WOODRUFF RD, HALL MC, CRAMER SD: A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology (2005) 146(1):13-18.
58. ORIMO A, GUPTA PB, SGROI DC et al.: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 121(3):335-348.
59. STERNLICHT MD, LOCHTER A, SYMPSON CJ et al.: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell (1999) 98(2):137-146.
60. FORSBERG K, VALYI-NAGY I, HELDIN CH, HERLYN M, WESTERMARK B: Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc. Natl. Acad. Sci. USA (1993) 90(2):393-397.
61. GRUM-SCHWENSEN B, KLINGELHOFER J, BERG CH et al.: Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. (2005) 65(9):3772-3780.
62. KUHN R, TORRES RM: Cre/loxP recombination system and gene targeting. Methods Mol. Biol. (2002) 180:175-204.
63. BERKING C, TAKEMOTO R, SCHAIDER H et al.: Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res. (2001) 61(22):8306-8316.
64. TUXHORN JA, MCALHANY SJ, YANG F, DANG TD, ROWLEY DR: Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. (2002) 62(21):6021-6025.
65. BHOWMICK NA, CHYTIL A, PLIETH D et al.: TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 303(5659):848-851.
66. CHENG N, BHOWMICK NA, CHYTIL A et al.: Loss of TGF-beta Type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncagene (2005) 24(32):5053-5068.
67. PIETRAS K, SJOBLOM T, RUBIN K, HELDIN CH, OSTMAN A: PDGF receptors as cancer drug targets. Cancer Cell (2003) 3(5):439-443.
68. SMITS A, FUNA K, VASSBOTN FS et al.: Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. Am. J. Pathol. (1992) 140(3):639-648.
69. COLTRERA MD, WANG J, PORTER PL, GOWN AM: Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res. (1995) 55(12):2703-2708.
70. LINDMARK G, SUNDBERG C, GLIMELIUS B et al.: Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab. Invest. (1993) 69(6):682-689.
71. HELDIN CH, ERIKSSON U, OSTMAN A: New members of the platelet-derived growth factor family of mitogens. Arch. Biochem. Biophys. (2002) 398(2):284-290.
72. DE JONG JS, VAN DIEST PJ, VAN DER VALK P, BAAK JP: Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J. Pathol. (1998) 184(1):44-52.
73. DE JONG JS, VAN DIEST PJ, VAN DER VALK P, BAAK JP: Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J. Pathol. (1998) 184(1):53-57.
74. FURUHASHI M, SJOBLOM T, ABRAMSSON A et al.: Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res. (2004) 64(8):2725-2733.
75. ABRAMSSON A, LINDBLOM P, BETSHOLTZ C: Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. (2003) 112(8):1142-1151.
76. ERBER R, THURNHER A, KATSEN AD et al.: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J. (2004) 18(2):338-340.
77. SKOBE M, FUSENIG NE: Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl. Acad. Sci. USA (1998) 95(3):1050-1055.
78. SHAO ZM, NGUYEN M, BARSKY SH: Human breast carcinoma desmoplasia is PDGF initiated. Oncogene (2000) 19(38):4337-4345.
79. BASERGA R, PERUZZI F, REISS K: The IGF-1 receptor in cancer biology. Int. J. Cancer (2003) 107(6):873-877.
80. SCHULER T, KORNIG S, BLANKENSTEIN T: Tumor rejection by modulation of tumor stromal fibroblasts. J. Exp. Med. (2003) 198(10):1487-1493.
81. ZOU W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer (2005) 5(4):263-274.
82. LAZAR-MOLNAR E, HEGYESI H, TOTH S, FALUS A: Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine (2000) 12(6):547-554.
83. ORIMO A, TOMIOKA Y. SHIMIZU Y et al.: Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin. Cancer Res. (2001) 7(10):3097-3105.
84. ZHU X, HUMPHREY PA. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology (2000) 56(6):1071-1074.
85. JOSEPH H, GORSKA AE, SOHN P, MOSES HL, SERRA R: Overexpression of a kinase-deficient transforming growth factor-beta Type II receptor in mouse mammary stroma, results in increased epithelial branching. Mol. Biol. Cell (1999) 10(4):1221-1234.
86. OHIRA H, MIYATA M, KURODA M et al.: Interleukin-6 induces proliferation of rat hepatocytes in vivo. J. Hepatol. (1996) 25(6):941-947.
87. NAKAMURA T, MATSUMOTO K, KIRITOSHI A, TANO Y: Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res. (1997) 57(15):3305-3313.
88. GMYREK GA, WALBURG M, WEBB CP et al.: Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am. J. Pathol. (2001) 159(2):579-590.
89. BEVIGLIA L, MATSUMOTO K, LIN CS, ZIOBER BL, KRAMER RH: Expression of the c-Met/HGF receptor in human breast carcinoma correlation with tumor progression. Int. J. Cancer (1997) 74(3):301-309.
90. YAMASHITA J, OGAWA M, YAMASHITA S et al.: Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. (1994) 54(7):1630-1633.
91. TAKADA N, YANO Y. MATSUDA T et al.: Expression of immunoreactive human hepatocyte growth factor in human esophageal squamous cell carcinomas. Cancer Lett. (1995) 97(2):145-148.
92. MASUYA D, HUANG C, LIU D et al.: The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br. J. Cancer (2004) 90(8):1555-1562.
93. BIRCHMEIER C, BIRCHMEIER W, GHERARDI E, VANDE WOUDE GF: Met, metastasis, motility and more. Nat. Ret, Mol. Cell Biol. (2003) 4(12):915-925.
94. KUPERWASSER C, CHAVARRIA T, WU M et al.: Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. USA (2004) 101(14):4966-4971.
95. MA PC, MAULIK G, CHRISTENSEN J, SALGIA R: c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. (2003) 22(4):309-325.
96. MICHIELI P, MAZZONE M, BASILICO C et al.: Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell (2004) 6(1):61-73.
97. LEBEDIS C, CHEN K, FALLAVOLLITA L, BOUTROS T, BRODT P: Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-1 and EGF. Int. J. Cancer (2002) 100(1):2-8.
98. GIRI D, ROPIQUET F, ITTMANN M: Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin. Cancer Res. (1999) 5(5):1063-1071.
99. PUPA SM, MENARD S, FORTI S, TAGLIABUE E: New insights into the role of extracellular matrix during tumor onset and progression. J. Cell. Physiol. (2002) 192(3):259-267.
100. NEWELL KJ, WITTY JP RODGERS WH, MATRISIAN LM: Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol. Carcinog. (1994) 10(4):199-206.
101. HEPPNER KJ, MATRISIAN LM, JENSEN RA, RODGERS WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. (1996) 149(1):273-282.
102. BISSON C, BLACHER. S, POLETTE M et al.: Restricted expression of membrane Type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int. J. Cancer (2003) 105(l):7-13.
103. STUELTEN CH, BYFIELD SD, ARANY PR et al: Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-{alpha} and TGF-{beta}. J. Cell Sci. (2005) 118(Pt 10):2143-2153.
104. MASSON R, LEFEBVRE O, NOEL A et al.: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. (1998) 140(6):1535-1541.
105. ANDARAWEWA KL, BOULAY A, MASSON R et al.: Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res. (2003) 63(18):5844-5849.
106. NOEL A, HAJITOU A, L'HOIR C et al.: Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int. J. Cancer (1998) 76(2):267-273.
107. ROSENTHAL EL, MCCRORY A, TALBERT M et al.: Expression of proteolytic enzymes in head and neck cancer-associated fibroblasts. Arch. Otolaryngol. Head Neck Surg. (2004) 130(8):943-947.
108. PYKE C, KRISTENSEN P, RALFKIAER E et al.: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. (1991) 138(5):1059-1067.
109. NIELSEN BS, SEHESTED M, TIMSHEL S, PYKE C, DANO K: Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab. Invest. (1996) 74(1):168-177.
110. TAN K, POWE DG, GRAY T, TURNER DR, HEWITT RE: Regional variations of urokinase-type plasminogen activator in human colorectal cancer: a quantitative study by image analysis. Int. J. Cancer (1995) 60(3):308-314.
111. ALMHOLT K, LUND LR, RYGAARD J et al.: Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int. J. Cancer (2005) 113(4):525-532.
112. BUGGE TH, LUND LR, KOMBRINCK KK et al.: Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene (1998) 16(24):3097-3104.
113. ALMHOLT K, NIELSEN BS, FRANDSEN TL et al.: Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene (2003) 22(28):4389-4397.
114. TURK V. KOS J, TURK B: Cysteine cathepsins (proteases)-on the main stage of cancer? Cancer Cell (2004) 5(5):409-410.
115. JOYCE JA, BARUCH A, CHEHADE K et al.: Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Gzncer Cell (2004) 5(5):443-453.
116. TSE GM, LUI PC, LEE CS et al.: Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. Hum. Pathol. (2004) 35(9):1053-1057.
117. PILCH H, SCHLENGER K, STEINER E et al.: Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int. J. Gynecol. Cancer (2001) 11(2):137-142.
118. FUKUMURA D, XAVIER R, SUGIURA T et al.: Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 94(6):715-725.
119. ALIZADEH AA. EISEN MB, DAVIS RE et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 403(6769):503-511.
120. NUTT CL, MANI DR, BETENSKY RA et al.: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. (2003) 63(7):1602-1607.
121. GOLUB TR, SLONIM DK TAMAYO P et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 286(5439):531-537.
122. VAN DE VIJVER MJ, HE YD, VAN'T VEER LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. (2002) 347(25):1999-2009.
123. VAN'T VEER LJ, DAI H, VAN DE VIJVER MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 415(6871):530-536.
124. YU Y, KHAN J, KHANNA C et al: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprot000ein Six-1 as key metastatic regulators. Nat. Med. (2004) 10(2):175-181.
125. XU XQ, EMERALD BS, GOH EL et al.: Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone (hGH) in human mammary carcinoma. J. Biol. Chem. (2005) 280(25):23987-24003.
126. MISCHEL PS, CLOUGHESY TF, NELSON SF: DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat. Rev. Neurosci. (2004) 5(10):782-792.
127. GREER BT, KHAN J: Diagnostic classification of cancer using DNA microarrays and artificial intelligence. Ann. NY Acad. Sci. (2004) 1020:49-66.
128. STEARS RL, MARTINSKY T, SCHENA M: Trends in microarray analysis. Nat. Med. (2003) 9(1):140-145.
129. NAKAGAWA H, LIYANARACHCHI S, DAVULURI RV et al.: Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene (2004) 23(44):7366-7377.
130. WEAVER VM, HOWLETT AR, LANGTON-WEBSTER B, PETERSEN OW, BISSELL MJ: The development of a functionally relevant cell culture model of progressive human breast cancer. Semin. Cancer Biol. (1995) 6(3):175-184.
131. ALLINEN M, BEROUKHIM R, CAI L et al.: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 6(1):17-32.
132. PETERSEN OW, NIELSEN HL, GUDJONSSON T et al.: Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am. J. Patbol. (2003) 162(2):391-402.
133. MICKE P, OSTMAN A, LUNDEBERG J, PONTEN F: Laser-assisted cell microdissection using the PALM system. Methods Mol. Biol. (2005) 293:151-166.
134. FUKUSHIMA N, SATO N, PRASAD N et al.: Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oneogene (2004) 23(56):9042-9051.
135. CHANG HY, CHI JT, DUDOIT S et al.: Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl. Acad. Sci. USA (2002) 99(20):12877-12882.
136. BOGDAHN U, HAU P, BRAWANSKI A et al.: Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009. Journal of Clinical Oncology (2004) ASCO Annual Meeting Proceedings (2004).
137. YINGLING JM, BLANCHARD KL, SAWYER JS: Development of TGF-beta signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. (2004) 3(12):1011-1022.
138. CHRISTENSEN JG, BURROWS J, SALGIA R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. (2005) 225(1):1-26.
139. BEHRENS P, MATHIAK M, MANGOLD E et al.: Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int. J. Cancer (2003) 107(2):183-188.
140. LEIGHL NB, PAZ-ARES L, DOUILLARD, JY et al.: Randomized Phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18. J. Clin. Oncol. (2005) 23(12):2831-2839.
141. BISSETT D, O'BYRNE KJ, VON PAWEL J et al.: Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(4):842-849.
142. MILLER KD, SAPHNER TJ, WATERHOUSE DM et al.: A randomized Phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin. Cancer Res. (2004) 10(6):1971-1975.
143. ROSENBAUM E, ZAHURAK M, SINIBALDI V et al.: Marimastat in the Treatment of Patients with Biochemically Relapsed Prostate Cancer: A Prospective Randomized, Double-Blind, Phase I/II Trial. Clin. Cancer Res. (2005) 11(12):4437-4443.
144. SCOTT AM, WISEMAN G, WELT S et al.: A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. (2003) 9(5):1639-1647.
145. HOFHEINZ RD, AL-BATRAN SE, HARTMANN F et al.: Stromal antigen targeting by a humanised monoclonal antibody: an early Phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie (2003) 26(1):44-48.
146. DE WEVER O, MAREEL M: Role of tissue stroma in cancer cell invasion. J. Pathol. (2003) 200(4):429-447.
147. JOYCE JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell (2005) 7(6):513-520.